Pitolisant prolongs the QT interval. Its use should be avoided in patients with known QT
prolongation or in combination with other drugs known to prolong QT interval. Pitolisant should also be avoided in patients with a history of cardiac arrhythmias. The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant.
- TRADE NAME: Wakix (Bioprojet)
- INDICATIONS: Treatment of excessive daytime sleepiness in patients with narcolepsy.
- CLASS: Histamine H3 receptor antagonist, Histamine H3 receptor inverse agonist
- HALF-LIFE: ~20 hours
- FDA APPROVAL DATE: 08/14/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP2D6 inhibitors, CYP3A4 inducers, CYP3A4 substrates - PREGNANCY: Pitolisant may reduce the effectiveness of hormonal contraceptives.
Please login to view the rest of this drug profile.
Page last updated 01/06/2024
